ICON Public Limited (NASDAQ:ICLR) Shares Sold by Somerset Trust Co

Somerset Trust Co decreased its position in shares of ICON Public Limited (NASDAQ:ICLR) by 4.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,994 shares of the medical research company’s stock after selling 85 shares during the quarter. Somerset Trust Co’s holdings in ICON Public were worth $418,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in ICON Public by 64.0% during the 4th quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of ICON Public by 39.2% in the second quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after buying an additional 111 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after acquiring an additional 96 shares during the period. First Horizon Advisors Inc. raised its position in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after acquiring an additional 151 shares in the last quarter. Finally, Steph & Co. lifted its holdings in ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after acquiring an additional 55 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Evercore ISI decreased their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Citigroup reduced their price target on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. JPMorgan Chase & Co. dropped their price objective on ICON Public from $375.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Truist Financial reaffirmed a “buy” rating and set a $284.00 target price (down from $295.00) on shares of ICON Public in a research note on Wednesday, December 18th. Finally, Leerink Partners reissued an “outperform” rating and issued a $255.00 price target (down previously from $270.00) on shares of ICON Public in a research note on Tuesday, November 19th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ICON Public currently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Stock Down 2.2 %

Shares of NASDAQ:ICLR opened at $198.11 on Friday. The company has a market capitalization of $16.34 billion, a price-to-earnings ratio of 22.09, a PEG ratio of 1.59 and a beta of 1.20. ICON Public Limited has a 12-month low of $183.38 and a 12-month high of $347.72. The business has a 50-day moving average price of $209.71 and a 200 day moving average price of $268.23. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the firm earned $3.10 EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. Sell-side analysts expect that ICON Public Limited will post 13.41 EPS for the current year.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.